Wedbush Has Positive Outlook for Immunome FY2024 Earnings

Immunome, Inc. (NASDAQ:IMNM) – Equities research analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Immunome in a report released on Wednesday, November 13th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings per share of ($2.11) for the year, up from their prior estimate of ($2.23). Wedbush has a “Outperform” rating and a $33.00 price target on the stock. The consensus estimate for Immunome’s current full-year earnings is ($2.13) per share. Wedbush also issued estimates for Immunome’s Q4 2024 earnings at ($0.70) EPS, Q1 2025 earnings at ($0.72) EPS, Q2 2025 earnings at ($0.68) EPS, Q3 2025 earnings at ($0.67) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($2.77) EPS, FY2026 earnings at ($2.70) EPS and FY2027 earnings at ($2.11) EPS.

IMNM has been the topic of a number of other research reports. Piper Sandler decreased their target price on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research note on Thursday. Stephens began coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus price target of $28.83.

Immunome Stock Down 11.1 %

NASDAQ IMNM opened at $9.90 on Monday. Immunome has a 52 week low of $6.93 and a 52 week high of $30.96. The company has a market capitalization of $617.96 million, a P/E ratio of -1.22 and a beta of 1.82. The stock’s 50-day moving average price is $13.12 and its 200-day moving average price is $13.79.

Insider Buying and Selling

In related news, CFO Max Rosett sold 14,380 shares of Immunome stock in a transaction dated Thursday, September 19th. The stock was sold at an average price of $16.01, for a total value of $230,223.80. Following the completion of the transaction, the chief financial officer now owns 47,476 shares in the company, valued at approximately $760,090.76. This trade represents a 23.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 8.60% of the stock is owned by company insiders.

Institutional Trading of Immunome

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Redmile Group LLC grew its stake in shares of Immunome by 26.0% during the first quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after buying an additional 1,010,139 shares during the last quarter. FMR LLC boosted its position in Immunome by 0.3% in the 3rd quarter. FMR LLC now owns 4,224,700 shares of the company’s stock valued at $61,765,000 after buying an additional 13,757 shares during the period. Janus Henderson Group PLC grew its stake in Immunome by 10.3% in the 3rd quarter. Janus Henderson Group PLC now owns 3,488,121 shares of the company’s stock worth $50,971,000 after acquiring an additional 324,614 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Immunome by 113.6% during the first quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after acquiring an additional 1,194,451 shares in the last quarter. Finally, Vanguard Group Inc. boosted its holdings in shares of Immunome by 16.1% in the first quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after purchasing an additional 279,712 shares during the period. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.